Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group

D.G. Te Raa; L. van der Straten; M. van Gelder; S. Kersting; M.D. Levin; R. Mous; H.M. van der Straaten; M.R. Nijziel; E. van der Spek; E.F.M. Posthuma; H.P.J. Visser; M. van der Klift; K. de Heer; M. Bellido; J.K. Doorduijn; A.H.W. Bruns; R.A.P. Raijmakers; A.P. Kater; HOVON CLL Study Group

doi:10.1080/10428194.2022.2084731

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group

D.G. Te Raa^*, L. van der Straten, M. van Gelder, S. Kersting, M.D. Levin, R. Mous, H.M. van der Straaten, M.R. Nijziel, E. van der Spek, E.F.M. Posthuma, H.P.J. Visser, M. van der Klift, K. de Heer, M. Bellido, J.K. Doorduijn, A.H.W. Bruns, R.A.P. Raijmakers, A.P. Kater, HOVON CLL Study Group

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.

Original language	English
Pages (from-to)	2276-2289
Number of pages	14
Journal	Leukemia & Lymphoma
Volume	63
Issue number	10
Early online date	22 Jun 2022
DOIs	https://doi.org/10.1080/10428194.2022.2084731
Publication status	Published - 24 Aug 2022

Keywords

Chronic lymphocytic leukemia
small lymphocytic lymphoma
diagnostics
treatment
guideline
CLINICAL-PRACTICE GUIDELINES
SCORING SYSTEM
FLOW-CYTOMETRY
FREE SURVIVAL
OPEN-LABEL
IBRUTINIB
RITUXIMAB
CYCLOPHOSPHAMIDE
FLUDARABINE
IDELALISIB

Access to Document

10.1080/10428194.2022.2084731

Cite this

Te Raa, D. G., van der Straten, L., van Gelder, M., Kersting, S., Levin, M. D., Mous, R., van der Straaten, H. M., Nijziel, M. R., van der Spek, E., Posthuma, E. F. M., Visser, H. P. J., van der Klift, M., de Heer, K., Bellido, M., Doorduijn, J. K., Bruns, A. H. W., Raijmakers, R. A. P., Kater, A. P., & HOVON CLL Study Group (2022). Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia & Lymphoma, 63(10), 2276-2289. https://doi.org/10.1080/10428194.2022.2084731

@article{5dfdacacc99042098de98dcb11e280e9,

title = "Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group",

abstract = "Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.",

keywords = "Chronic lymphocytic leukemia, small lymphocytic lymphoma, diagnostics, treatment, guideline, CLINICAL-PRACTICE GUIDELINES, SCORING SYSTEM, FLOW-CYTOMETRY, FREE SURVIVAL, OPEN-LABEL, IBRUTINIB, RITUXIMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, IDELALISIB",

author = "{Te Raa}, D.G. and {van der Straten}, L. and {van Gelder}, M. and S. Kersting and M.D. Levin and R. Mous and {van der Straaten}, H.M. and M.R. Nijziel and {van der Spek}, E. and E.F.M. Posthuma and H.P.J. Visser and {van der Klift}, M. and {de Heer}, K. and M. Bellido and J.K. Doorduijn and A.H.W. Bruns and R.A.P. Raijmakers and A.P. Kater and {HOVON CLL Study Group}",

year = "2022",

month = aug,

day = "24",

doi = "10.1080/10428194.2022.2084731",

language = "English",

volume = "63",

pages = "2276--2289",

journal = "Leukemia & Lymphoma",

issn = "1042-8194",

publisher = "Routledge/Taylor & Francis Group",

number = "10",

}

Te Raa, DG, van der Straten, L, van Gelder, M, Kersting, S, Levin, MD, Mous, R, van der Straaten, HM, Nijziel, MR, van der Spek, E, Posthuma, EFM, Visser, HPJ, van der Klift, M, de Heer, K, Bellido, M, Doorduijn, JK, Bruns, AHW, Raijmakers, RAP, Kater, AP & HOVON CLL Study Group 2022, 'Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group', Leukemia & Lymphoma, vol. 63, no. 10, pp. 2276-2289. https://doi.org/10.1080/10428194.2022.2084731

TY - JOUR

T1 - Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group

AU - Te Raa, D.G.

AU - van der Straten, L.

AU - van Gelder, M.

AU - Kersting, S.

AU - Levin, M.D.

AU - Mous, R.

AU - van der Straaten, H.M.

AU - Nijziel, M.R.

AU - van der Spek, E.

AU - Posthuma, E.F.M.

AU - Visser, H.P.J.

AU - van der Klift, M.

AU - de Heer, K.

AU - Bellido, M.

AU - Doorduijn, J.K.

AU - Bruns, A.H.W.

AU - Raijmakers, R.A.P.

AU - Kater, A.P.

AU - HOVON CLL Study Group

PY - 2022/8/24

Y1 - 2022/8/24

N2 - Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.

AB - Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.

KW - Chronic lymphocytic leukemia

KW - small lymphocytic lymphoma

KW - diagnostics

KW - treatment

KW - guideline

KW - CLINICAL-PRACTICE GUIDELINES

KW - SCORING SYSTEM

KW - FLOW-CYTOMETRY

KW - FREE SURVIVAL

KW - OPEN-LABEL

KW - IBRUTINIB

KW - RITUXIMAB

KW - CYCLOPHOSPHAMIDE

KW - FLUDARABINE

KW - IDELALISIB

U2 - 10.1080/10428194.2022.2084731

DO - 10.1080/10428194.2022.2084731

M3 - (Systematic) Review article

C2 - 35737364

SN - 1042-8194

VL - 63

SP - 2276

EP - 2289

JO - Leukemia & Lymphoma

JF - Leukemia & Lymphoma

IS - 10

ER -